Saitama, Japan – October 26, 2021 – Epsilon Molecular Engineering, Inc. (HQ: Saitama, Japan; President & CEO: Naoto Nemoto; “EME”) announces that it entered into Feasibility Study Agreement with Kyowa Kirin Co., Ltd. (HQ: Tokyo, Japan; President & CEO: Masashi Miyamoto; “Kyowa Kirin”) for the creation of a new VHH.
EME will identify humanized VHH(*1) antibodies using its unique VHH screening platform (Screening technology that combines ”PharmaLogical® Library”(*2） with cDNA display（*3））. Kyowa Kirin will evaluate and confirm the activity of the antibodies.
Under the term of this agreement, EME receives an undisclosed upfront payment and will conclude a separate joint research agreement following the progress of future research and development.
＊1 VHH：Variable Domain of Heavy Chain of Heavy Chain Antibody found in camelids. Superior stability and easily molecularly designed than conventional IgG
＊2 PharmaLogical® Library：Original Humanized Artificial VHH Library with Structure based Design that contributes to the paratope formation on VHHs
＊3 cDNA display：A Stable and Simple Genotype–Phenotype Coupling Using a Cell-Free Translation System, enabling 1013-14 repertories of VHHs to be screened at once
【Features of PharmaLogical® Library】
- Design based on crystal structure analysis data of VHH antibody
A humanized VHH library designed based on the structural characteristics resulting from the crystal structure analysis data of the human sequence and VHH that have already been clinically applied to the antibody framework part (FR). The three CDRs (Complementarity Determining Regions) that form the antigen recognition site are designed based on the structural property information obtained from the alpaca-derived VHH, and are known to contribute most to antigen binding. By randomizing the CDR3s, large diversity is demonstrated. - Design to minimize the frequency on occurrence of amino acids that cause heterogeneity in formulation
Amino acids that are susceptible to modification and that can cause major structural changes, such as cysteine and proline residues, cause heterogeneity in the formulation process. By designing a CDR that minimizes the frequency of appearance of these amino acids, it can be expected to minimize the problems that arise in the - Innovative VHH screening method by combining PharmaLogical® Library with cDNA display
The combination of PharmaLogical® Library which has a diverse library size of 1013-14 (10 trillion to 100 trillion), and a screening system based on the cDNA display technology enables an innovative VHH screening.
【About Epsilon Mol ecular Engineering】
EME is a biopharmaceutical startup that has been developing innovative modality and drugs based on evolutionary molecular engineering since 2016. Taking advantage of our unique screening technology and molecular design method, we are engaged in research and development of diagnostic agents and reagents for regenerative medicine as well as drug development. With the corporate mission of “creating future biomolecules,” we aim to contribute to a wide range of society and people’s lives.
Website： https://www.epsilon-mol.co.jp/eng/
【Contact】
Epsilon Molecular Engineering, Inc.
Business Development Department
TEL：048-857-8880 E-mail : info@epsilon-mol.co.jp
